Aviles 1996.

Study characteristics
Methods	Not placebo‐controlled, not blinded, unclear sponsorship, single‐center trial
Participants	Adults; hematologic tumors; ANC < 0.1 x 109/L
Interventions	G‐CSF (not specified) 5 mcg/kg SC ATB: Amikacin plus Ceftazidime
Outcomes	Overall mortality Infection‐related mortality
Notes	Hospital discharge criteria: not reported Duration of grade IV neutropenia reported as days to absolute granulocyte recovery to > 0.5 x 109/L
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	We were not able to assess the adequacy of method of sequence generation based on the information provided in the article
Allocation concealment (selection bias)	Low risk	Sealed envelopes were used
Blinding (performance bias and detection bias) All outcomes	High risk	There was no blinding
Blinding of participants and personnel (performance bias) All outcomes	High risk	There was no blinding
Blinding of outcome assessment (detection bias) All outcomes	High risk	There was no blinding
Incomplete outcome data (attrition bias) All outcomes	High risk	ITT analysis was not used, withdrawals are described
Other bias	High risk	Prespecified values of sample size, alpha and beta errors were not provided